|Market Size in 2022||Market Forecast in 2030||CAGR (in %)||Base Year|
|USD 1.46 Billion||USD 1.85 Billion||3.06%||2022|
Carboprost Tromethamine Market
The global carboprost tromethamine market size was worth around USD 1.46 billion in 2022 and is predicted to grow to around USD 1.85 billion by 2030 with a compound annual growth rate (CAGR) of roughly 3.06% between 2023 and 2030.
The report analyzes the global carboprost tromethamine market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the carboprost tromethamine industry.
Carboprost tromethamine, also known by its brand name Hemabate, is a medication used in obstetrics and gynecology. It is a synthetic analog of prostaglandin F2-alpha, a hormone naturally produced in the body. Carboprost tromethamine is primarily used to induce labor, terminate pregnancies, or manage postpartum hemorrhage (excessive bleeding after childbirth). The medication works by causing contractions of the smooth muscles in the uterus, which helps in the expulsion of the fetus during labor or the removal of uterine tissue during pregnancy termination. In cases of postpartum hemorrhage, it helps the uterus contract and control bleeding. Carboprost tromethamine is typically administered as an injection into the muscle of the upper outer quadrant of the buttock. It should only be used under the supervision of a healthcare professional in a hospital or clinical setting, as it can cause side effects such as nausea, vomiting, diarrhea, fever, chills, headache, and uterine cramping.
The increasing prevalence of postpartum hemorrhage (PPH) drives the market growth
Postpartum hemorrhage, which is excessive bleeding after childbirth, is a major cause of maternal mortality and morbidity worldwide. The rising prevalence of PPH is driving the demand for medications like carboprost tromethamine, which is used to manage and control postpartum bleeding. For instance, India had almost 24,016,020 thousand births in 2021, followed by China with 15,918,889 thousand, according to data from the World Health Organization on Maternal, Newborn, Child, and Adolescent Health and Ageing.
The number of postpartum hemorrhage cases also rises as a result of the high birth rate. In addition, according to a March 2022 article in the BMC Journal of Reproductive Health, postpartum mortality—which accounts for around 25.0-43.0% of all mother deaths—is one of the primary causes of maternal mortality in underdeveloped nations. The paper also mentioned how somewhat high postpartum bleeding is common among mothers in Ethiopia after giving delivery. This rise in postpartum hemorrhage incidence is anticipated to drive up treatment demand and boost injectable sales of carboprost tromethamine. Thus, the increasing prevalence of postpartum hemorrhage (PPH) will drive the global carboprost tromethamine market growth over the forecast period.
The availability of alternative treatments is expected to hamper the market
In some cases, alternative medications or procedures may be available for managing postpartum hemorrhage or pregnancy termination. The availability of alternative treatments can impact the demand for carboprost tromethamine, as healthcare providers and patients may opt for alternative options based on factors such as efficacy, safety, and cost-effectiveness. Thus, this is expected to hamper the growth of the carboprost tromethamine industry during the forecast period.
Increasing government initiatives and healthcare policies offer an attractive opportunity for the market expansion
Governments and healthcare organizations are implementing various initiatives to reduce maternal mortality and improve maternal healthcare. This includes programs that focus on managing postpartum hemorrhage effectively. Such initiatives drive the demand for medications like carboprost tromethamine, leading to carboprost tromethamine market growth. For instance, the improvement of maternal health indicators has been a priority for the Indian government. Over the past 20 years, significant progress has been made in preventing unnecessary maternal deaths: Globally, the number of women and girls who die each year from complications during pregnancy and delivery has significantly decreased, falling from 451,000 in 2000 to 295,000 in 2017, a 38% decline. Thus, government initiatives and healthcare policies drive market growth during the study time frame.
Side effects of the carboprost tromethamine pose a major challenge
Carboprost tromethamine, like any medication, carries the risk of side effects and contraindications. It may not be suitable for individuals with certain medical conditions or those who have a history of allergies or adverse reactions. The potential risks and contraindications can limit the usage of carboprost tromethamine in some patients and affect market demand.
The global carboprost tromethamine industry is segmented based on application, distribution channel, and region.
Based on the application, the global market is bifurcated into postpartum hemorrhage treatment and pregnancy abortion. The postpartum hemorrhage treatment segment is expected to capture the largest market share during the forecast period. The segment growth is attributed to the increasing prevalence of postpartum hemorrhage (PPH). For instance, according to a July 2021 article in the journal Medicine, the combination of injections of Leonurus japonicus and carboprost tromethamine can effectively prevent postpartum hemorrhage in high-risk pregnant women. According to the study, using Leonurus japonicus Injection as a preventative measure in conjunction with carboprost tromethamine may be effective in preventing postpartum hemorrhage after deliveries. The relevance of the study into the usage of carboprost tromethamine is significant, and much research is being done on further forms of treatment. Thereby, driving the market growth over the forecast period.
Based on the distribution channel, the global carboprost tromethamine industry is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies.
|Report Attributes||Report Details|
|Report Name||Carboprost Tromethamine Market Research Report|
|Market Size in 2022||USD 1.46 Billion|
|Market Forecast in 2030||USD 1.85 Billion|
|Growth Rate||CAGR of 3.06%|
|Number of Pages||226|
|Key Companies Covered||Pfizer Inc., MANUS AKTTEVA BIOPHARMA LLP, Biosynth, Monvi labs, Taj Pharmaceuticals Limited, Amneal Pharmaceuticals LLC, Bio-Techne, SimSon Pharma Limited, WATSON INTERNATIONAL LIMITED, Ryvis Pharma, Apionex Pharma Pvt Ltd., ChemScene, Dr. Reddy's Laboratories Ltd., Merck KGaA, Universal Biologicals, Woodward Pharma, BioSpectra, Inc. and ANGUS Chemical Company among others.|
|Segments Covered||By Application, By Distribution Channel, and By Region|
|Regions Covered||North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)|
|Historical Year||2017 to 2021|
|Forecast Year||2023 - 2030|
|Customization Scope||Avail customized purchase options to meet your exact research needs. Request For Customization|
North America is expected to dominate the market over the forecast period
North America is expected to dominate the carboprost tromethamine market over the forecast period. The regional growth is attributed to the increasing incidence of postpartum hemorrhage. For instance, the World Health Organization (WHO) estimates that there will be 3,985,712 thousand births in the United States in 2021. A growing incidence of postpartum hemorrhage incidents has been associated with increased birth rates. By 2050, it is anticipated that there will be about 4,124,888 thousand live births. Moreover, in April 2022, the National Institute for Child Health Quality reported that 3.0% of newborns in the US had instances of postpartum hemorrhage. These instances reflected a yearly birth rate of above 100,000. The aforementioned report also said that hospitals may be able to stop up to 70.0% of obstetric fatalities caused by hemorrhage.
In the United States, maternal mortality might be decreased with the appropriate treatment approaches. Pregnant women using carboprost tromethamine are supposed to have their postpartum bleeding symptoms suppressed. As a result, it is anticipated that the North American market for carboprost tromethamine would expand throughout the projection period. Furthermore, the market for carboprost tromethamine in the US is expanding as a result of several factors, including important product introductions, a high concentration of market participants or manufacturing presence, acquisitions and collaborations between large firms, and high pregnancy rates in the nation. For instance, the United States had about 30.6% of unplanned pregnancies throughout the year, per the United Health Foundation's America's Health Rankings for 2021.
The global carboprost tromethamine market is dominated by players like:
By Distribution Channel
Carboprost is a synthesized oxytocic prostaglandin. Carboprost tromethamine also known as Hemabate, is a kind of prostaglandin that is used to treat excessive bleeding after childbirth in women and postpartum hemorrhage. It's also used as a contraceptive pill to trigger abortion by producing uterine contractions and progressive placental evacuation. The medication is given during the third and fifth months of pregnancy. It causes greater contractions by acting on the F receptor or the E2 receptor sites in the uterus muscles. As a result, the uterus's conception products are evacuated. Additionally, it enhances gastrointestinal stimulation, which can result in nausea and vomiting.
A rise in the incidence of postpartum hemorrhage is the major factor that is driving the growth of the market for carboprost tromethamine. Further, initiatives taken by the government regarding the use of carboprost tromethamine in rural areas are fostering market growth. In addition to this, favorable support by regulatory bodies for the approval of the drug is also supporting the growth of the market.
According to the report, the global market size was worth around USD 1.46 billion in 2022 and is predicted to grow to around USD 1.85 billion by 2030.
The global carboprost tromethamine market is expected to grow at a CAGR of 3.06% during the forecast period.
The global carboprost tromethamine market growth is expected to be driven by North America. It is currently the world’s highest revenue-generating market owing to the increasing demand for contraceptive pills to treat severe bleeding after childbirth in the United States and Canada.
The global carboprost tromethamine market is dominated by players like Pfizer Inc., MANUS AKTTEVA BIOPHARMA LLP, Biosynth, Monvi labs, Taj Pharmaceuticals Limited, Amneal Pharmaceuticals LLC, Bio-Techne, SimSon Pharma Limited, WATSON INTERNATIONAL LIMITED, Ryvis Pharma, Apionex Pharma Pvt Ltd., ChemScene, Dr. Reddy's Laboratories Ltd., Merck KGaA, Universal Biologicals, Woodward Pharma, BioSpectra, Inc. and ANGUS Chemical Company among others.